Brief: Maia Biotechnology Doses First Patients In Europe In Ongoing Phase 2 Trial (Thio-101) Evaluating Thio For Non-Small Cell Lung Cancer Treatment
07/03/2023 13:16
March 7 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY DOSES FIRST PATIENTS IN EUROPE IN
ONGOING
PHASE 2 TRIAL (THIO-101) EVALUATING THIO FOR NON-SMALL CELL LUNG
CANCER TREATMENT
* MAIA BIOTECHNOLOGY INC - DOSED ITS FIRST PATIENT IN
THIO-101
TRIAL IN AUSTRALIA IN JULY 2022 AND COMMENCED DOSING PATIENTS IN
EUROPE IN MARCH 2023
Source text for Eikon: ID:nBw2yFsQwa
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale